Discovery Laboratories Announces Presentation & Key Results of Phase 2a Study of Aerosolized KL4 Surfactant in Cystic Fibrosis at the North American Cystic Fibrosis Conference

WARRINGTON, Pa., Oct. 22, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) today announces that the Phase 2a clinical study of aerosolized KL4 surfactant (lucinactant) in patients with cystic fibrosis (CF) was presented at the 2010 North American Cystic Fibrosis Conference (NACFC). The trial was conducted as an investigator-initiated study under the direction of Dr. Scott H. Donaldson at The University of North Carolina (UNC) with support from PARI Pharma GmbH, and was funded by Cystic Fibrosis Foundation Therapeutics, Inc., a nonprofit affiliate of the Cystic Fibrosis Foundation.